CSBio CSBio

X
[{"orgOrder":0,"company":"Scandion Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SCO-101 works in synergy with the chemotherapy drug docetaxel in drug resistant cancer cells","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"DENMARK","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Scandion Oncology"},{"orgOrder":0,"company":"Scandion Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scandion Oncology Drug SCO-101 Potentiates the Effect of Chemotherapy in the First Cohort in Chemo-Resistant Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Scandion Oncology"},{"orgOrder":0,"company":"Symphogen","sponsor":"Servier Canada","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Servier Agrees to Buy Symphogen to Swell its Cancer Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"DENMARK","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Symphogen"},{"orgOrder":0,"company":"Symphogen","sponsor":"Servier","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Servier Completes the Acquisition of Symphogen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"DENMARK","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Symphogen"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allarity Therapeutics Doses First Patient in Phase 1b Clinical Trial Evaluating Dovitinib and Stenoparib Combination in Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Allarity Therapeutics"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Pathos","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pathos Launches Precision Oncology Pipeline With License of First Phase I Program, a CBP\/p300 Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Novo Nordisk"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            The license agreement aims to develop FT-7051 (renamed P-300), an oral, small molecule CBP/p300 inhibitor program from Novo Nordisk as Pathos’ first clinical-stage asset in its pipeline.

            Lead Product(s): P-300

            Therapeutic Area: Oncology Product Name: P-300

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Pathos

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement May 23, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Stenoparib is a dual-targeted inhibitor of PARP 1, 2 and tankyrase 1, 2 where dovitinib is a pan-tyrosine kinase inhibitor. The combination may increase the chances of cancer apoptosis and providing synergistic, enhanced antitumor activity.

            Lead Product(s): Dovitinib,Stenoparib

            Therapeutic Area: Oncology Product Name: TKI258

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 20, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The main result of oral SCO-101 potentiates the effects of FOLFIRI. Based on safety data from this first cohort of patients, Data Safety Monitoring Board has recommended to include 3 additional patients at 150 mg SCO-101and FOLFIRI.

            Lead Product(s): Endovion,Fluorouracil,Calcium Folinate

            Therapeutic Area: Oncology Product Name: SCO-101

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 31, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            As a result of this acquisition Symphogen becomes Servier’s center of excellence for antibodies, strengthening the Group’s pipeline in various therapeutic areas, including oncology.

            Lead Product(s): Sym021

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Servier

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition June 04, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Servier will gain full ownership of Symphogen’s proprietary pipeline of oncology and immuno-oncology programs and Symphogen’s antibody discovery and development platform.

            Lead Product(s): Sym021

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Servier Canada

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition April 03, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Based on modelling of preclinical data with docetaxel resistant cancer cells, Scandion Oncology has published that SCO-101 significantly increases the potency of docetaxel.

            Lead Product(s): SCO-101

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 25, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY